Literature DB >> 16450826

Impetigo in soldiers after hand-to-hand combat training.

Flavio Lejbkowicz1, Luisa Samet, Larissa Belavsky, Ora Bitterman-Deutsch.   

Abstract

Bacterial skin infections are very common and trigger destruction of the skin integrity. Impetigo is a consequence of group A beta-hemolytic streptococcus or Staphylococcus aureus infection. The clinical presentation in general is very typical and empiric treatment is usually successful. In cases of close contacts such as between classmates, athletes, or soldiers, the prompt recognition and appropriate treatment of the infection may stop an epidemic. We report a group of six soldiers who shared the same military equipment (physical shields) during hand-to-hand combat training. All of the soldiers had skin lesions and two of them suffered from systemic symptoms. Group A beta-hemolytic streptococcus and S. aureus were cultured from the impetiginous lesions. All patients recovered after systemic and/or local antibiotic treatments. These cases emphasize the need for the maintenance of proper hygiene throughout the training program to prevent spread of the disease and the importance of rapid diagnosis by bacteriological identification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16450826     DOI: 10.7205/milmed.170.11.972

Source DB:  PubMed          Journal:  Mil Med        ISSN: 0026-4075            Impact factor:   1.437


  2 in total

1.  Changing epidemiology of acute post-streptococcal glomerulonephritis in Northeast Florida: a comparative study.

Authors:  Mohammad Ilyas; Asad Tolaymat
Journal:  Pediatr Nephrol       Date:  2008-03-29       Impact factor: 3.714

2.  Characterization of Meningitis and Meningoencephalitis in the Israeli Defense Forces From 2004 to 2015: A Population-Based Study.

Authors:  Shany Guly Gofrit; Yoav Yechezkel Pikkel; Hagai Levine; Shifra Fraifeld; Shlomzion Kahana Merhavi; Limor Friedensohn; Ruth Eliahou; Tamir Ben-Hur; Asaf Honig
Journal:  Front Neurol       Date:  2022-06-30       Impact factor: 4.086

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.